Mycosis fungoides laboratory findings: Difference between revisions
Jump to navigation
Jump to search
| Line 8: | Line 8: | ||
[[Medical laboratory|Laboratory]] tests for [[cutaneous T cell lymphoma]] include:<ref name="VuralAkay2018">{{cite journal|last1=Vural|first1=Seçil|last2=Akay|first2=Bengü Nisa|last3=Botsali|first3=Ayşenur|last4=Atilla|first4=Erden|last5=Parlak|first5=Nehir|last6=Okcu Heper|first6=Aylin|last7=Şanlı|first7=Hatice|title=Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis|journal=Turkish Journal of Hematology|volume=35|issue=1|year=2018|pages=35–41|issn=13007777|doi=10.4274/tjh.2016.0502}}</ref> | [[Medical laboratory|Laboratory]] tests for [[cutaneous T cell lymphoma]] include:<ref name="VuralAkay2018">{{cite journal|last1=Vural|first1=Seçil|last2=Akay|first2=Bengü Nisa|last3=Botsali|first3=Ayşenur|last4=Atilla|first4=Erden|last5=Parlak|first5=Nehir|last6=Okcu Heper|first6=Aylin|last7=Şanlı|first7=Hatice|title=Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis|journal=Turkish Journal of Hematology|volume=35|issue=1|year=2018|pages=35–41|issn=13007777|doi=10.4274/tjh.2016.0502}}</ref> | ||
* [[Complete blood count]] ([[Complete blood count|CBC]]) | * [[Complete blood count]] ([[Complete blood count|CBC]]) | ||
* Peripheral [[blood]] smear | * Peripheral [[blood]] [[Smear test|smear]] | ||
:* Atypical [[T cell|T-cells]] (Sezary [[Cell (biology)|cells]]) | :* Atypical [[T cell|T-cells]] (Sezary [[Cell (biology)|cells]]) | ||
:* [[Allogeneic]] [[hematopoietic stem cell transplantation]] (allo-[[Hematopoietic stem cell transplantation|HSCT]]) demonstrated progressive [[disease]] had undergone. | :* [[Allogeneic]] [[hematopoietic stem cell transplantation]] (allo-[[Hematopoietic stem cell transplantation|HSCT]]) demonstrated progressive [[disease]] had undergone. | ||
| Line 14: | Line 14: | ||
:* High level [[lactate dehydrogenase]] ([[LDH]])in andvanced [[disease]] stage [[Patient|patients]] | :* High level [[lactate dehydrogenase]] ([[LDH]])in andvanced [[disease]] stage [[Patient|patients]] | ||
* [[Biopsy]] of [[skin]] ( multiple [[Biopsy|biopsies]]) | * [[Biopsy]] of [[skin]] ( multiple [[Biopsy|biopsies]]) | ||
**A rare evaluated finding observed mono [[nuclear]] [[Cell (biology)|cells]] aggrigation by cerebriform [[nuclei]] in the [[Epidermis (skin)|epidermis]] surrounding [[Langerhans cell|langerhans cells]]. | **A rare evaluated finding observed [[Mononucleosis|mono]] [[nuclear]] [[Cell (biology)|cells]] aggrigation by cerebriform [[nuclei]] in the [[Epidermis (skin)|epidermis]] surrounding [[Langerhans cell|langerhans cells]]. | ||
**Atypical [[Lymphocyte|lymphocytes]] observed in the [[Epidermis (skin)|epidermis]] or [[Superficial anatomy|superficial]] [[Dermis|dermi]]<nowiki/>s. | **Atypical [[Lymphocyte|lymphocytes]] observed in the [[Epidermis (skin)|epidermis]] or [[Superficial anatomy|superficial]] [[Dermis|dermi]]<nowiki/>[[Dermis|s]]. | ||
*Lymph node biopsies is recommended. | *[[Lymph node]] [[Biopsy|biopsies]] is recommended. | ||
* complete [[Metabolic control analysis|metabolic]] [[Panel data|panel]] | * complete [[Metabolic control analysis|metabolic]] [[Panel data|panel]] | ||
* [[Flow cytometry]] | * [[Flow cytometry]] | ||
* [[Immunohistochemistry]] | * [[Immunohistochemistry]] | ||
* [[Immunophenotyping]]: Beta F1+, [[CD2]]-/+, [[CD3]]+, [[CD3]]- ([[CD4]]-positive variant), [[CD4]]+ ([[CD4]]-positive variant), [[CD4]]-, [[CD5]]-, [[CD7]]+/-, [[CD8]]+, [[CD8]]- ([[CD4]]-positive variant), Granzyme B+, and | * [[Immunophenotyping]]: Beta F1+, [[CD2]]-/+, [[CD3]]+, [[CD3]]- ([[CD4]]-positive variant), [[CD4]]+ ([[CD4]]-positive variant), [[CD4]]-, [[CD5]]-, [[CD7]]+/-, [[CD8]]+, [[CD8]]- ([[CD4]]-positive variant), [[Granzyme B|Granzyme B+]], and [[perforin]]+ | ||
* Loss of CD26 and CD7 expression | * Loss of CD26 and [[CD7]] [[expression]] | ||
* [[Polymerase chain reaction|PCR]] | * [[Polymerase chain reaction|PCR]] | ||
* [[Southern blot]] | * [[Southern blot]] | ||
Revision as of 17:45, 21 December 2018
|
Cutaneous T cell lymphoma Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
Laboratory tests for cutaneous T cell lymphoma include complete blood count (CBC), blood chemistry studies, flow cytometry, immunohistochemistry, and immunophenotyping.
Laboratory Tests
Laboratory tests for cutaneous T cell lymphoma include:[1]
- Complete blood count (CBC)
- Peripheral blood smear
- Atypical T-cells (Sezary cells)
- Allogeneic hematopoietic stem cell transplantation (allo-HSCT) demonstrated progressive disease had undergone.
- High level lactate dehydrogenase (LDH)in andvanced disease stage patients
- Biopsy of skin ( multiple biopsies)
- A rare evaluated finding observed mono nuclear cells aggrigation by cerebriform nuclei in the epidermis surrounding langerhans cells.
- Atypical lymphocytes observed in the epidermis or superficial dermis.
- Lymph node biopsies is recommended.
- complete metabolic panel
- Flow cytometry
- Immunohistochemistry
- Immunophenotyping: Beta F1+, CD2-/+, CD3+, CD3- (CD4-positive variant), CD4+ (CD4-positive variant), CD4-, CD5-, CD7+/-, CD8+, CD8- (CD4-positive variant), Granzyme B+, and perforin+
- Loss of CD26 and CD7 expression
- PCR
- Southern blot
References
- ↑ Vural, Seçil; Akay, Bengü Nisa; Botsali, Ayşenur; Atilla, Erden; Parlak, Nehir; Okcu Heper, Aylin; Şanlı, Hatice (2018). "Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis". Turkish Journal of Hematology. 35 (1): 35–41. doi:10.4274/tjh.2016.0502. ISSN 1300-7777.